

Table I. Common Treatments for Platinum Resistant Disease

Agent	Response	Side effects	Comments
PLD	10-20%	PPE; Mucositis	Most freq prescribed until supply shortages
Topotecan	12-18%	Myelosuppression	Daily x 5 or weekly administration used
Docetaxel	22%	Myelosuppression	Single GOG trial with very good results
Gemcitabine	15%	Myelosuppression	Also data with platinum in resistant disease; Approved for Platinum sensitive disease with carboplatinum
Bevacizumab	10-15%	HTN; Proteinuria	Concern for bowel perforation in heavily pretreated patients
Etoposide	6-27%	Myelosuppression	Activity dose and population dependent
Paclitaxel	10-20%	Neuropathy: Myelosuppression	Usually administered weekly in this setting